MACAU LEGEND (01680) raised approximately HK$86.4 million from the issuance of new shares.
Macao Lijun (01680) announced that all conditions set out in the articles of association and underwriting agreement have been met, and the joint underwriters have not terminated the underwriting agreement, so the share offering will become unconditional at 5:00 PM on January 16, 2026 (Friday).
After consolidation, a total of 33 valid acceptances and applications involving approximately 153 million shares of the share offering shares have been accepted and applied for, accounting for approximately 49.49% of the total number of shares offered for sale of approximately 310 million shares.
MACAU LEGEND (01680) announced that all the conditions set forth in the articles of association and underwriting agreement have been met, and the joint underwriters have not terminated the underwriting agreement, so the share offering will become unconditional on January 16, 2026 (Friday) at 5:00 pm.
After the merger calculation, a total of 33 valid acceptances and applications involving approximately 153 million shares of the share offering have been accepted and applied for, accounting for approximately 49.49% of the total number of shares offered for sale of approximately 310 million shares.
Approximately 157 million shares of the share offering remain undersubscribed, accounting for approximately 50.51% of the total number of shares offered for sale of approximately 310 million shares.
Donghai Securities and Pinnacle Securities (i.e., joint underwriters under the underwriting agreement) have agreed to purchase all the approximately 157 million unsold shares.
The total amount raised from the share offering is approximately HK$93 million, with a net fundraising of approximately HK$86.4 million.
Related Articles

LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

Chengdu Road & Bridge Engineering (002628.SZ) has approximately 2.94 million yuan worth of new bid-winning and new contract orders in the fourth quarter.
LINGBAO GOLD (03330): Huang Hui appointed as independent non-executive director.

LEADS BIOLABS-B(09887): Vitrakvi has been granted orphan drug designation (ODD) by the European Commission for the treatment of pulmonary neuroendocrine tumors.

Chengdu Road & Bridge Engineering (002628.SZ) has approximately 2.94 million yuan worth of new bid-winning and new contract orders in the fourth quarter.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


